Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


10.1136/medethics-2020-106322

http://scihub22266oqcxt.onion/10.1136/medethics-2020-106322
suck pdf from google scholar
32461245!7316118!32461245
unlimited free pdf from europmc32461245    free
PDF from PMC    free
html from PMC    free

suck abstract from ncbi


Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534

Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
pmid32461245      J+Med+Ethics 2020 ; 46 (8): 502-504
Nephropedia Template TP

gab.com Text

Twit Text FOAVip

Twit Text #

English Wikipedia


  • Ethical guidelines for deliberately infecting volunteers with COVID-19 #MMPMID32461245
  • Richards AD
  • J Med Ethics 2020[Aug]; 46 (8): 502-504 PMID32461245show ga
  • Global fatalities related to COVID-19 are expected to be high in 2020-2021. Developing and delivering a vaccine may be the most likely way to end the pandemic. If it were possible to shorten this development time by weeks or months, this may have a significant effect on reducing deaths. Phase II and phase III trials could take less long to conduct if they used human challenge methods-that is, deliberately infecting participants with COVID-19 following inoculation. This article analyses arguments for and against such methods and provides suggested broad guidelines for regulators, researchers and ethics committees when considering these matters. It concludes that it may be possible to maintain current ethical standards yet still permit human challenge trials in a context where delay is critical. The implications are that regulators and researchers need to work together now to design robust but short trials and streamline ethics approval processes so that they are in place when applications for trials are made.
  • |*Guidelines as Topic[MESH]
  • |*Research Design[MESH]
  • |*Viral Vaccines[MESH]
  • |Betacoronavirus[MESH]
  • |Biomedical Research/*ethics/methods[MESH]
  • |COVID-19[MESH]
  • |COVID-19 Vaccines[MESH]
  • |Coronavirus Infections/*prevention & control/virology[MESH]
  • |Ethical Analysis[MESH]
  • |Ethical Review[MESH]
  • |Ethics Committees, Research[MESH]
  • |Ethics, Research[MESH]
  • |Human Experimentation/*ethics[MESH]
  • |Humans[MESH]
  • |Informed Consent[MESH]
  • |Intention[MESH]
  • |Pandemics/*ethics/prevention & control[MESH]
  • |Pneumonia, Viral/*prevention & control/virology[MESH]
  • |Research Personnel[MESH]
  • |Research Subjects[MESH]
  • |SARS-CoV-2[MESH]
  • |Vaccination[MESH]


  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    Linkout box